产品介绍：
产品说明
生化/生理作用
ATP-competitive dual BCR-ABL and Src kinase inhibitor
PD166326 is an ATP-competitive dual BCR-ABL and Src kinase inhibitor. In some studies it has been found to be more potent than imatinib with inhibition of cancer growth in the low nanomolar range or even picomolar range in various biological systems.
法律信息
Pfizer is a registered trademark of Pfizer, Inc.
基本信息
| 经验(实验)分子式 | C21H16Cl2N4O2 |
| 分子量 | 427.28 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| manufacturer/tradename | Pfizer® |
| 颜色 | white to light brown |
| 溶解性 | DMSO: 2 mg/mL, clear |
| 创始人 | Pfizer |
| 储存温度 | room temp |
| SMILES string | O=C1N(C)C2=C(C=NC(NC3=CC=CC(CO)=C3)=N2)C=C1C4=C(Cl)C=CC=C4Cl |
安全信息
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
